Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake

Autores
Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; Villalobos, Carlos
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Fil: Sanz Blasco, Sara Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Consejo Superior de Investigaciones Científicas; España
Fil: Calvo Rodriguez, Maria. Consejo Superior de Investigaciones Científicas; España
Fil: Caballero, Erica. Consejo Superior de Investigaciones Científicas; España
Fil: Garcia-Durillo, Monica. Consejo Superior de Investigaciones Científicas; España
Fil: Nunez, Lucia. Consejo Superior de Investigaciones Científicas; España
Fil: Villalobos, Carlos. Consejo Superior de Investigaciones Científicas; España
Materia
Alzheimer'S Disease
Non-Steroidal Anti-Inflammatory Drugs
Calcium
Mitochondria
Amyloid Β Oligomers
N-Methyl-D-Aspartate
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/47161

id CONICETDig_3505372a50c07b967b9de525967ea9ce
oai_identifier_str oai:ri.conicet.gov.ar:11336/47161
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium UptakeSanz Blasco, Sara IsabelCalvo Rodriguez, MariaCaballero, EricaGarcia-Durillo, MonicaNunez, LuciaVillalobos, CarlosAlzheimer'S DiseaseNon-Steroidal Anti-Inflammatory DrugsCalciumMitochondriaAmyloid Β OligomersN-Methyl-D-Aspartatehttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.Fil: Sanz Blasco, Sara Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Consejo Superior de Investigaciones Científicas; EspañaFil: Calvo Rodriguez, Maria. Consejo Superior de Investigaciones Científicas; EspañaFil: Caballero, Erica. Consejo Superior de Investigaciones Científicas; EspañaFil: Garcia-Durillo, Monica. Consejo Superior de Investigaciones Científicas; EspañaFil: Nunez, Lucia. Consejo Superior de Investigaciones Científicas; EspañaFil: Villalobos, Carlos. Consejo Superior de Investigaciones Científicas; EspañaBentham Science Publishers2018-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/47161Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; et al.; Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake; Bentham Science Publishers; Current Alzheimer Research; 15; 6; 4-2018; 504-5101567-2050CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2174/1567205015666171227154016info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/158662/articleinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:39:41Zoai:ri.conicet.gov.ar:11336/47161instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:39:41.926CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
title Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
spellingShingle Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
Sanz Blasco, Sara Isabel
Alzheimer'S Disease
Non-Steroidal Anti-Inflammatory Drugs
Calcium
Mitochondria
Amyloid Β Oligomers
N-Methyl-D-Aspartate
title_short Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
title_full Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
title_fullStr Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
title_full_unstemmed Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
title_sort Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake
dc.creator.none.fl_str_mv Sanz Blasco, Sara Isabel
Calvo Rodriguez, Maria
Caballero, Erica
Garcia-Durillo, Monica
Nunez, Lucia
Villalobos, Carlos
author Sanz Blasco, Sara Isabel
author_facet Sanz Blasco, Sara Isabel
Calvo Rodriguez, Maria
Caballero, Erica
Garcia-Durillo, Monica
Nunez, Lucia
Villalobos, Carlos
author_role author
author2 Calvo Rodriguez, Maria
Caballero, Erica
Garcia-Durillo, Monica
Nunez, Lucia
Villalobos, Carlos
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Alzheimer'S Disease
Non-Steroidal Anti-Inflammatory Drugs
Calcium
Mitochondria
Amyloid Β Oligomers
N-Methyl-D-Aspartate
topic Alzheimer'S Disease
Non-Steroidal Anti-Inflammatory Drugs
Calcium
Mitochondria
Amyloid Β Oligomers
N-Methyl-D-Aspartate
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Fil: Sanz Blasco, Sara Isabel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Consejo Superior de Investigaciones Científicas; España
Fil: Calvo Rodriguez, Maria. Consejo Superior de Investigaciones Científicas; España
Fil: Caballero, Erica. Consejo Superior de Investigaciones Científicas; España
Fil: Garcia-Durillo, Monica. Consejo Superior de Investigaciones Científicas; España
Fil: Nunez, Lucia. Consejo Superior de Investigaciones Científicas; España
Fil: Villalobos, Carlos. Consejo Superior de Investigaciones Científicas; España
description Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer´s disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ). We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and R-flurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death. Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
publishDate 2018
dc.date.none.fl_str_mv 2018-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/47161
Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; et al.; Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake; Bentham Science Publishers; Current Alzheimer Research; 15; 6; 4-2018; 504-510
1567-2050
CONICET Digital
CONICET
url http://hdl.handle.net/11336/47161
identifier_str_mv Sanz Blasco, Sara Isabel; Calvo Rodriguez, Maria; Caballero, Erica; Garcia-Durillo, Monica; Nunez, Lucia; et al.; Is it All Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake; Bentham Science Publishers; Current Alzheimer Research; 15; 6; 4-2018; 504-510
1567-2050
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.2174/1567205015666171227154016
info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/158662/article
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082884067131392
score 13.22299